Can Superextended Lymph Node Dissection be Justified for Gastric Cancer with Pathologically Positive Para-aortic Lymph Nodes?

被引:56
作者
Tokunaga, Masanori [1 ]
Ohyama, Shigekazu [1 ]
Hiki, Naoki [1 ]
Fukunaga, Tetsu [1 ]
Aikou, Susumu [1 ]
Yamaguchi, Toshiharu [1 ]
机构
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg Gastroenterol, Tokyo, Japan
关键词
D2; LYMPHADENECTOMY; SURGERY; CHEMOTHERAPY; MORBIDITY; TRIAL; S-1; D3;
D O I
10.1245/s10434-010-0969-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The prognosis of patients with gastric cancer and para-aortic lymph node (PALN) metastasis is poor. Recent Japanese randomized trials concluded that prophylactic PALN dissection is not effective for curable advanced gastric cancer. However, the value of curative resection in patients with pathologically positive PALN is not determined yet. We retrospectively identified 178 patients with pathologically positive PALN who underwent curative resection at the Cancer Institute Hospital from 1980 to 2004. Patient characteristics were analyzed and independent prognostic factors for death were identified by Cox proportional hazard model. Partial gastrectomy was the most frequently performed procedure (142 of 178). Postoperative morbidity and mortality rates were 30 and 2%, respectively, with a 5-year survival rate of 13.0%. Multivariate analysis revealed the total number of positive nodes (hazard ratio, 1.804; 95% confidence interval, 1.221-2.665) and macroscopic type (hazard ratio, 1.697; 95% confidence interval, 1.138-2.530) as independent prognostic factors, while age, sex, histology, pathological tumor depth, and degree of PALN dissection were not statistically significant. The 5-year survival rate increased to 28.6% in patients with a parts per thousand currency sign15 positive nodes and macroscopic type other than type 4. Prophylactic PALN dissection can not be justified in curable advanced gastric cancer. However, R0 resection including PALN retrieval might be beneficial in patients with pathologically positive PALN, providing patients are carefully selected and operations are performed safely.
引用
收藏
页码:2031 / 2036
页数:6
相关论文
共 21 条
[1]   RANDOMIZED COMPARISON OF MORBIDITY AFTER D1 AND D2 DISSECTION FOR GASTRIC-CANCER IN 996 DUTCH PATIENTS [J].
BONENKAMP, JJ ;
SONGUN, I ;
HERMANS, J ;
SASAKO, M ;
WELVAART, K ;
PLUKKER, JTM ;
VANELK, P ;
OBERTOP, H ;
GOUMA, DJ ;
TAAT, CW ;
VANLANSCHOT, J ;
MEYER, S ;
DEGRAAF, PW ;
VONMEYENFELDT, MF ;
TILANUS, H ;
VANDEVELDE, CJH .
LANCET, 1995, 345 (8952) :745-748
[2]   The treatment of advanced gastric cancer:: current strategies and future perspectives [J].
Cervantes, A. ;
Rosello, S. ;
Roda, D. ;
Rodriguez-Braun, E. .
ANNALS OF ONCOLOGY, 2008, 19 :103-107
[3]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[4]   Postoperative morbidity and mortality after D-1 and D-2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial [J].
Cuschieri, A ;
Fayers, P ;
Fielding, J ;
Craven, J ;
Bancewicz, J ;
Joypaul, V ;
Cook, P .
LANCET, 1996, 347 (9007) :995-999
[5]   Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group Trial [J].
Hartgrink, HH ;
van de Velde, CJH ;
Putter, H ;
Bonenkamp, JJ ;
Kranenbarg, EK ;
Songun, I ;
Welvaart, K ;
van Krieken, JHJM ;
Meijer, S ;
Plukker, JTM ;
van Elk, PJ ;
Obertop, H ;
Gouma, DJ ;
van Lanschot, JJB ;
Taat, CW ;
de Graaf, PW ;
von Meyenfeldt, MF ;
Tilanus, H ;
Sasako, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2069-2077
[6]  
Japanese Gastric Cancer Association, 1998, Gastric Cancer, V1, P10
[7]   S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial [J].
Koizumi, Wasaburo ;
Narahara, Hiroyuki ;
Hara, Takuo ;
Takagane, Akinori ;
Akiya, Toshikazu ;
Takagi, Masakazu ;
Miyashita, Kosei ;
Nishizaki, Takashi ;
Kobayashi, Osamu ;
Takiyama, Wataru ;
Toh, Yasushi ;
Nagaie, Takashi ;
Takagi, Seiichi ;
Yamamura, Yoshitaka ;
Yanaoka, Kimihiko ;
Orita, Hiroyuki ;
Takeuchi, Masahiro .
LANCET ONCOLOGY, 2008, 9 (03) :215-221
[8]   Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial [J].
Kulig, Jan ;
Popiela, Tadeusz ;
Kolodziejczyk, Piotr ;
Sierzega, Marek ;
Szczepanik, Antoni .
AMERICAN JOURNAL OF SURGERY, 2007, 193 (01) :10-15
[9]   Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: A multi-institutional study [J].
Kunisaki, C ;
Akiyama, H ;
Nomura, M ;
Matsuda, G ;
Otsuka, Y ;
Ono, H ;
Nagahori, Y ;
Hosoi, H ;
Takahashi, M ;
Kito, F ;
Shimada, H .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (05) :659-667
[10]   Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. [J].
Macdonald, JS ;
Smalley, SR ;
Benedetti, J ;
Hundahl, SA ;
Estes, NC ;
Stemmermann, GN ;
Haller, DG ;
Ajani, JA ;
Gunderson, LL ;
Jessup, JM ;
Martenson, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (10) :725-730